SynthesisRadiation oncology (London, England)2022
Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis.
Synthesis in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proton beam and carbon ion radiotherapy in skull base chordoma: a systematic review, meta-analysis and meta-regression with trial sequential analysis.Neurosurgical review · 2024Pooled it
- [Particle radiotherapy for sarcomas : Advantages, challenges and future perspectives].Radiologie (Heidelberg, Germany) · 2026Article
- Article
- The rise of 3D spheroids in radiobiology for assessing tumour radioresistance.Acta oncologica (Stockholm, Sweden) · 2026Article
- Carbon-ion beam irradiation combined with miR-17-5p/miR-17-3p inhibitors effectively kill osteosarcoma cells.American journal of cancer research · 2026Article
- Review
- Image-guided treatment of mouse tumours with radioactive ion beams.Nature physics · 2025Article
- UK guidelines for the management of bone sarcomas.British journal of cancer · 2025Review
- Advanced Radiotherapy Technologies in Spine Tumors: What the Surgeon Needs to Know.Global spine journal · 2025Article
- Osteosarcoma: current insights and advances.Exploration of targeted anti-tumor therapy · 2025Review
- The rationale for a carbon ion radiation therapy facility in Australia.Journal of medical radiation sciences · 2024Review
- Sacral-Nerve-Sparing Planning Strategy in Pelvic Sarcomas/Chordomas Treated with Carbon-Ion Radiotherapy.Cancers · 2024Article
- Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.BMC musculoskeletal disorders · 2024Article
- A future directions of renal cell carcinoma treatment: combination of immune checkpoint inhibition and carbon ion radiotherapy.Frontiers in immunology · 2024Review
- Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions.Journal of Cancer · 2024Article
- Review
- Article
- Current topics and management of head and neck sarcomas.Japanese journal of clinical oncology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to systematically evaluate and conduct a meta-analysis of the efficacy and safety of carbon ion radiotherapy for bone sarcomas.
methodsWe searched for articles using the PubMed, Embase, Cochrane Library, and the Web of Science databases from their inception to January 12, 2022. Two researchers independently screened the literature and extracted data based on the inclusion and exclusion criteria. Statistical analyses were performed using STATA version 14.0.
resultsWe searched for 4378 candidate articles, of which 12 studies were included in our study according to the inclusion and exclusion criteria. Of the 897 BSs patients who received carbon ion radiotherapy in the studies, 526 patients had chordoma, 255 patients had chondrosarcoma, 112 patients had osteosarcoma, and 4 patients had other sarcomas. The local control rate at 1, 2, 3, 4, 5, and 10 years in these studies were 98.5% (95% confidence interval [CI] = 0.961-1.009, I
conclusionAs an advanced radiotherapy, carbon ion radiotherapy is promising for patients with bone sarcomas that are unresectable or residual after incomplete surgery. The data indicated that carbon ion radiotherapy was safe and effective for bone sarcomas, showing promising results for local control, overall survival, and lower acute and late toxicity. PROSPERO REGISTRATION NUMBER: CRD42021258480.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.